ZIM Laboratories Limited (ZIMLAB.BO)
INR 113.15
(0.85%)
INR 113.15
(0.85%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 88.13 Million | 375.19 Million | 492.06 Million | 318.51 Million | 219.15 Million | 349.36 Million |
| Net Income | 172.46 Million | 353.55 Million | 210.42 Million | 154.12 Million | 686 Thousand | 220.7 Million |
| Depreciation & Amortization | 159.51 Million | 174.69 Million | 160.33 Million | 157.89 Million | 144.11 Million | 114.18 Million |
| Deferred income taxes | - | - | - | - | -54.45 Million | 1.14 Million |
| Stock-based compensation | - | - | - | - | 152 Thousand | 6.36 Million |
| Change in working capital | -267.85 Million | -128.42 Million | 65.8 Million | -82.4 Million | 5.57 Million | -96.37 Million |
| Other non-cash items | 610.89 Million | -24.62 Million | 55.49 Million | 88.91 Million | 123.08 Million | 103.33 Million |
| Investing Cash Flow | -730.61 Million | -362.03 Million | -145.71 Million | -58.8 Million | -194.05 Million | -206.77 Million |
| Investments in PPE | -739.23 Million | -366.67 Million | -152.25 Million | -64.77 Million | -185.27 Million | -203.71 Million |
| Acquisitions | 5.48 Million | 200 Thousand | 1.6 Million | 59 Thousand | -500 Thousand | 684 Thousand |
| Investment purchases | -2.83 Million | -2.75 Million | -1.05 Million | 1.95 Million | -19.46 Million | -10.15 Million |
| Sales/Maturities of investments | 5.97 Million | 3.59 Million | 2.99 Million | 1.97 Million | 16.11 Million | 4.84 Million |
| Other Investing Activities | 5.97 Million | 3.59 Million | 2.99 Million | 1.97 Million | -4.91 Million | 1.56 Million |
| Financing Cash Flow | 670.47 Million | 5.45 Million | -329.7 Million | -259.74 Million | -21.62 Million | -151.57 Million |
| Debt repayment | -473.69 Million | -154.7 Million | -299.3 Million | -234.94 Million | -314.13 Million | -119.99 Million |
| Dividends payments | -493 Thousand | -585 Thousand | -1.67 Million | -244 Thousand | -9.11 Million | -9.34 Million |
| Common Stock Repurchased | - | 164.91 Million | - | 23.45 Million | 298.18 Million | - |
| Common Stock Issuance | 214.02 Million | -4.75 Million | - | 612 Thousand | 612 Thousand | - |
| Other Financing Activities | 214.51 Million | 585 Thousand | -28.72 Million | -48.62 Million | 1.16 Million | -23.89 Million |
| Accounts receivables | -71.36 Million | 26.94 Million | -19.89 Million | -129.15 Million | 170.94 Million | -259.78 Million |
| Accounts payables | 79.08 Million | -371.14 Million | 295.07 Million | 26.32 Million | -152 Million | 197.61 Million |
| Inventory | -275.56 Million | 215.78 Million | -209.37 Million | 20.41 Million | -13.36 Million | -34.91 Million |
| Other working capital | 79.08 Million | - | - | - | - | 707 Thousand |
| Cash at beginning of period | 66.19 Million | 34.2 Million | 13.92 Million | 14.61 Million | 4.99 Million | 14.68 Million |
| Cash at end of period | 104.64 Million | 64.2 Million | 34.2 Million | 13.92 Million | 14.61 Million | 4.99 Million |
| Capital Expenditure | -739.23 Million | -366.67 Million | -152.25 Million | -64.77 Million | -185.27 Million | -203.71 Million |
| Effect of forex changes on cash | 3.8 Million | 11.38 Million | 3.63 Million | -647 Thousand | 6.1 Million | -707 Thousand |
| Net cash flow / Change in cash | 38.45 Million | 30 Million | 20.27 Million | -685 Thousand | 9.61 Million | -9.69 Million |
| Free Cash Flow | -651.09 Million | 8.51 Million | 339.8 Million | 253.74 Million | 33.87 Million | 145.64 Million |
| Breakdown | 2023 FY | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 FY | 2022 Q4 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 172.46 Million | 47.84 Million | 41.49 Million | 2.26 Million | 353.55 Million | 72.36 Million |
| Depreciation & Amortization | 159.51 Million | 39.35 Million | 40.85 Million | 40.25 Million | 174.69 Million | 49.3 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | -267.85 Million | - | - | - | -128.42 Million | - |
| Other non-cash items | 610.89 Million | -39.35 Million | -40.85 Million | -40.25 Million | -24.62 Million | -49.3 Million |
| Investing Cash Flow | -730.61 Million | - | - | - | -362.03 Million | - |
| Investments in PPE | -739.23 Million | - | - | - | -366.67 Million | - |
| Acquisitions | 5.48 Million | - | - | - | 200 Thousand | - |
| Investment purchases | -2.83 Million | - | - | - | -2.75 Million | - |
| Sales/Maturities of investments | 5.97 Million | - | - | - | 3.59 Million | - |
| Other Investing Activities | - | - | - | - | 3.59 Million | - |
| Financing Cash Flow | 670.47 Million | - | - | - | 5.45 Million | - |
| Debt repayment | -473.69 Million | - | - | - | -154.7 Million | - |
| Dividends payments | -493 Thousand | - | - | - | -585 Thousand | - |
| Common Stock Repurchased | - | - | - | - | 164.91 Million | - |
| Common Stock Issuance | 214.02 Million | - | - | - | -4.75 Million | - |
| Other Financing Activities | 214.51 Million | - | - | - | 585 Thousand | - |
| Accounts receivables | -71.36 Million | - | - | - | 26.94 Million | - |
| Accounts payables | 79.08 Million | - | - | - | -371.14 Million | - |
| Inventory | -275.56 Million | - | - | - | 215.78 Million | - |
| Other working capital | - | - | - | - | - | - |
| Cash at beginning of period | 66.19 Million | 171.67 Million | 130.18 Million | 66.19 Million | 34.2 Million | -6.17 Million |
| Cash at end of period | 104.64 Million | 47.84 Million | 171.67 Million | 2.26 Million | 64.2 Million | 66.19 Million |
| Capital Expenditure | -739.23 Million | - | - | - | -366.67 Million | - |
| Effect of forex changes on cash | 3.8 Million | - | - | - | 11.38 Million | - |
| Net cash flow / Change in cash | 38.45 Million | -123.83 Million | 41.49 Million | -63.92 Million | 30 Million | 72.36 Million |
| Free Cash Flow | -651.09 Million | 47.84 Million | 41.49 Million | 2.26 Million | 8.51 Million | 72.36 Million |
OVZON
0922
VLE
036630
BIOIF
ANRG